CME

Asthma is characterized by eosinophilic airway inflammation and elevated serum immunoglobulin E (IgE) levels. Due to these pathologic features, the foundation of asthma treatment has historically been anti-inflammatory therapy with inhaled corticosteroids (ICSs). Numerous factors, in addition to IgE and eosinophils; however, likely play important roles in mediating the airway inflammatory response characteristic of asthma. ICSs are effective therapy for some patients with persistent asthma, but clinical trials have shown that even increasing doses of ICSs under carefully controlled situations does not always result in acceptable asthma control. Consequently, other classes of medications, in addition to ICSs, are recommended in those patients with more severe asthma. The class of medication most commonly used in more severe asthma, along with ICSs, is long-acting inhaled beta-2-agonists, but leukotriene modifying agents and anti-IgE monoclonal antibodies may also be used. Multiple agents are also on the horizon. As our understanding of the complex pathophysiology of asthma increases, it will enable the development of novel therapeutic approaches for patients who are not responding well to traditional treatments. 0.5 CME credits.

Join Dr. Tracy S. Cummings for this CME activity that will help practitioners better identify and manage binge eating disorder (BED). Based on recent DSM-5 changes in the diagnostic criteria for binge eating disorder (BED), it is likely that the number of patients diagnosed with BED will substantially increase. Dr. Cummings explores the prevalence of BED, along with its link to obesity, and discusses screening and treatment options based on recent research and clinical trials. 0.5 CME credits.

Binge eating disorder is defined as recurring episodes of eating significantly more food in a short period of time than most people would eat under similar circumstances, with episodes marked by feelings of lack of control. In 2013 the American Psychiatric Association approved Binge Eating Disorder for inclusion in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Revision or the DSM-5, as its own category of eating disorder. This discussion will help you to more effectively screen, diagnosis and treat patients within your practice. 0.5 CME Credits

Nearly 77,000 new cases of melanoma are expected to be diagnosed in the U.S. in 2013. This CME expert interview explores the impact of new immunotherapies on emergent management strategies that focus on optimizing outcomes for patients with inoperable or metastatic melanoma. The interview focuses on processes of T-cell activation and checkpoint controls, as well as establishing patterns of tumor response to immunotherapy. 0.5 CME Credits

Please join Kenneth Anderson, MD, from the Dana-Farber Cancer Institute, as he presents an informative update on recent advances in the management of multiple myeloma. His discussion highlights findings presented at the American Society of Hematology (ASH) 55th annual conference in New Orleans, LA, where he reviews 1) new data for patients with newly-diagnosed multiple myeloma; 2) options for patients with relapsed and refractory disease; and 3) data on long-term survivors with multiple myeloma, those who have survived 10 or more years after their diagnosis. A special focus includes review of current and emergent novel therapies for multiple myeloma, and how they are reshaping outcomes for these patients. 0.25 CME credits.

CME credits: 0.50 Valid until: 02/27/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6914Binge eating disorder is defined as recurring episodes of eating significantly more food in a short period of time than most people would eat under similar circumstances, with episodes marked by feelings of lack of control. In 2013 the American Psychiatric Association approved Binge Eating Disorder for inclusion in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Revision or the DSM-5, as its own category of eating disorder. This discussion will help you to more effectively screen, diagnosis and treat patients within your practice. Estimated time to complete activity: 30 minutes

CME credits: 0.50 Valid until: 02/26/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6878Nearly 77,000 new cases of melanoma are expected to be diagnosed in the U.S. in 2013. This CME expert interview explores the impact of new immunotherapies on emergent management strategies that focus on optimizing outcomes for patients with inoperable or metastatic melanoma. The interview focuses on processes of T-cell activation and checkpoint controls, as well as establishing patterns of tumor response to immunotherapy. CME credits: 0.5 AMA PRA Category 1 Credits™ Estimated time to complete activity: 30 minutes Release date: February 26, 2014Expiration date: February 26, 2015

CME credits: 0.25 Valid until: 02/25/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6894Please join Kenneth Anderson, MD, from the Dana-Farber Cancer Institute, as he presents an informative update on recent advances in the management of multiple myeloma. His discussion highlights findings presented at the American Society of Hematology (ASH) 55th annual conference in New Orleans, LA, where he reviews 1) new data for patients with newly-diagnosed multiple myeloma; 2) options for patients with relapsed and refractory disease; and 3) data on long-term survivors with multiple myeloma, those who have survived 10 or more years after their diagnosis. A special focus includes review of current and emergent novel therapies for multiple myeloma, and how they are reshaping outcomes for these patients. Estimated time to complete activity: 15 minutes

Join Dr. Tracy S. Cummings for this CME activity that will help practitioners better identify and manage binge eating disorder (BED). Based on recent DSM-5 changes in the diagnostic criteria for binge eating disorder (BED), it is likely that the number of patients diagnosed with BED will substantially increase. Dr. Cummings explores the prevalence of BED, along with its link to obesity, and discusses screening and treatment options based on recent research and clinical trials.

Binge eating disorder is defined as recurring episodes of eating significantly more food in a short period of time than most people would eat under similar circumstances, with episodes marked by feelings of lack of control. In 2013 the American Psychiatric Association approved Binge Eating Disorder for inclusion in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Revision or the DSM-5, as its own category of eating disorder. This discussion will help you to more effectively screen, diagnosis and treat patients within your practice.

Melanoma is the most aggressive form of skin cancer, and its incidence continues to increase dramatically. It is likely more than 76,000 new cases will be diagnosed in the US in 2014. This CME interview will discuss new advances in targeted and immune therapies in the treatment of patients with melanoma, including matching patients with the most effective treatment based on their presentation.

While responsible for less than 10% of all skin cancers, melanoma is responsible for more than 75% of all skin cancer-related deaths. More than 9,500 people in the U.S. are likely to die from the disease in 2014. Treatment of melanoma is often associated with toxicities based on the agent used. One agent with a long history of managing melanoma is interleukin 2 or IL-2. Join us as Dr. John Kirkwood addresses anticipating and managing toxicity when treating with high-dose IL-2. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm

Many patients with fractures are not diagnosed as having osteoporosis or adequately treated to reduce the risk of future fractures. Multidisciplinary collaboration is necessary to properly diagnose and manage these patients. This discussion will focus on optimizing coordinated prevention and management strategies in patients with or at risk for osteoporotic fractures.

Asthma is characterized by eosinophilic airway inflammation and elevated serum immunoglobulin E (IgE) levels. Due to these pathologic features, the foundation of asthma treatment has historically been anti-inflammatory therapy with inhaled corticosteroids (ICSs). Numerous factors, in addition to IgE and eosinophils; however, likely play important roles in mediating the airway inflammatory response characteristic of asthma. ICSs are effective therapy for some patients with persistent asthma, but clinical trials have shown that even increasing doses of ICSs under carefully controlled situations does not always result in acceptable asthma control. Consequently, other classes of medications, in addition to ICSs, are recommended in those patients with more severe asthma. The class of medication most commonly used in more severe asthma, along with ICSs, is long-acting inhaled beta-2-agonists, but leukotriene modifying agents and anti-IgE monoclonal antibodies may also be used. Multiple agents are also on the horizon. As our understanding of the complex pathophysiology of asthma increases, it will enable the development of novel therapeutic approaches for patients who are not responding well to traditional treatments.

Melanoma is the most aggressive form of skin cancer, and while it represents less than 10% of all skin cancers it is responsible for more than 75% of all skin cancer-related deaths. And its incidence continues to increase dramatically: data estimates 76,699 new cases of melanoma have been diagnosed and approximately 9,500 patients have died of the disease in the U.S. during 2013. Please join us as Dr. Omid Hamid addresses critical clinical issues surrounding managing this difficult disease. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm Resources: NCCN Guidelines: www.nccn.org Society for Immunotherapy in Cancer Guidelines: www.sitcancer.org Estimated time to complete activity: 15 minutes